IL-22 in lavage as a biomarker in patients with lung cancer by Tufman, Amanda
Aus der Medizinischen Klinik V des Klinikums der Universität München 
Direktor: Prof. Dr. med. J. Behr 
Sektion Pneumologie Innenstadt und Thorakale Onkologie 
Leiter: Prof. Dr. Rudolf M. Huber 
 
 
 
IL-22 in lavage as a biomarker in patients  
with lung cancer 
 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Medizin 
an der Medizinischen Fakultät der 
Ludwig-Maximilian-Universität zu München 
 
 
 
vorgelegt von 
Amanda L.H. Tufman 
aus Toronto 
2013 
 
2 
 
 
Mit Genehmigung der Medizinischen Fakultät der 
 Ludwig-Maximilians-Universität München 
 
 
 
 
 
 
Berichterstatter:   Prof. Dr. med. Rudolf M. Huber    
 
Mitberichterstatter:   Prof. Dr. med. Thomas Knösel 
    Prof. Dr. Rudolf Hatz 
    Prof. Dr. rer. nat. Vigo Heissmeyer 
 
 
Dekan: Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR 
Tag der mündlichen Prüfung: 12. 12. 2013 
 
 
 
 
3 
Table of Contents 
  Page
1. INTRODUCTION 5 
1.1. Lung cancer  5 
1.2. The challenge of treating lung cancer 6 
1.2.1. Treatment modalities in early stage and locally advanced lung cancer6 
1.2.2. Treatment of advanced lung cancer 8 
1.2.3. Targeted therapies 9 
1.2.4. Immunologic therapies for lung cancer 11 
1.2.5. Prognostic and predictive biomarkers 11 
1.2.5.1.Prognostic factors 12 
1.2.5.2 Predictive factors 13 
1.3.  Early diagnosis and screening of lung cancer 14 
1.4. Biomaterial sampling 15 
1.4.1. Non-invasive and minimally invasive biomaterial sampling 15 
1.4.2. Bronchoalveolar lavage 16 
1.5. IL-22 – discovery, molecular and biological characteristics 18 
1.5.1. IL-22 in the lung 21 
1.5.2. IL-22 in lung cancer 25 
1.6. Aim of the dissertation 28 
2. PATIENTS AND METHODS 29 
2.1. Patients 29 
2.2. Bronchoscopic procedures and sample collection  30 
2.2.1. Bronchoscopic procedures 30 
2.2.2 Sample processing 31 
2.2.2.1 Cell count 32 
2.2.2.2.Differential cell count 32 
2.2.2.3.CD4/CD8 ratio 32 
2.2.2.4.IL-22 ELISA 33 
2.3. Statistical Methods 34 
3. RESULTS 35 
3.1. Cohort demographics 35 
3.2. IL-22 concentration in BAL and bronchial washings 36 
3.3. Correlation of IL-22 with diagnosis 37 
3.4. Correlation of IL-22 with cellular components of BAL 40 
3.5. Correlation of IL-22 with systemic markers of inflammation 45 
 
4 
 
 
4 DISCUSSION 49
4.1.  Discussion of the methods 49
4.1.1.Diversity of patients and diagnoses 49
4.1.2.Inclusion of washings and bronchoalveolar lavage 50
4.1.3.Dilution of samples 52
4.1.4.Correlation with systemic parameters 55
4.2 Discussion of the results  56
4.2.1.IL-22 in lavage 56
4.2.2.The correlation of IL-22 in bronchoalveolar lavage with clinical pathology 58
4.2.3.Correlation of IL-22 with other parameters in lavage and the systemic 
circulation 
60 
4.2.4 Correlation with patient demographics 63
4.2.5.Future directions 64 
5. CONCLUSION 66
6. REFERENCES 67
7. Summary 87
8. Zusammenfassung 89
9. APPENDIX 91
9.1. List of tables and figures 91 
9.2. Acknowledgements 92
9.3. Curriculum Vitae 93
 
 
 
5 
 
 
1. Introduction 
 
1.1. Lung Cancer 
 
Lung cancer is not only a common disease, but remains, despite advances in our 
understanding of its’ biology and novel therapeutic options, an exceedingly deadly 
disease. A predicted 186 970 men and 82 640 women will die of lung cancer in the 
European Union in 2013 1. Although the majority of lung cancer patients are men, the 
incidence of lung cancer in women is climbing. Since 2009 there has been a 7% 
increase in the incidence of lung cancer in European women, likely in part due to 
changes in smoking behaviour. In Great Britain more women now die of lung cancer 
than breast cancer (standardised death rate 21.2 per 100 000). Lung cancer is also 
an important cause of mortality worldwide2. In 2010 respiratory cancers caused 1.5 
million deaths, and accounted for 19% of all deaths from cancer3. Although smoking 
is the predominant cause of most lung cancers, other environmental factors such as 
radon and asbestos are relevant in some patients4, and genetic and epigenetic 
factors which may contribute to the disease are under investigation5.  
 
Primary lung cancers are categorized histologically as small cell lung cancer or non 
small cell lung cancer. In Germany small cell lung cancer accounts for approximately 
20 % of lung cancer cases6. Non small cell lung cancer (NSCLC) describes a 
clinically and biologically heterogeneous group of histologies including squamous cell 
lung cancer, adenocarcinoma and large cell carcinoma. The adenocarcinomas can 
be further classified histologically, and these subtypes are of increasing clinical 
relevance due to their association with tumour biology and clinical prognosis7. 
Mutations in  subsets of NSCLC, especially in adenocarcinomas, can now be 
targeted by specific drugs. These so-called driver mutations are also of increasing 
interest in squamous cell tumours. Currently the most clinically relevant driver 
mutations are activating mutations of the epidermal growth factor receptor (EGFR) 
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gene and fusion of the echinoderm microtubule-associated protein-like 4 (EML4) 
gene with the gene for anaplastic lymphoma kinase (ALK)8.  
 
1.2. The challenge of treating lung cancer 
 
Most patients with lung cancer are diagnosed at an advanced stage of disease 9. 
This is because lung cancer often remains asymptomatic until late in the course of 
disease; and when it does cause symptoms these are often non-specific and overlap 
significantly with the symptoms of chronic bronchitis experienced by many smokers 
10. Likely due at least in part to the non-specific nature of lung cancer symptoms, 
there is often a clinically relevant delay between the onset of symptoms, the 
suspicion of lung cancer and, finally, the initiation of appropriate treatment11. 
 
The treatment of lung cancer, both in early stages and advanced disease, is often 
associated with significant morbidity and even mortality. Therefore, clinicians must 
weigh the chances of benefit against the risk of treatment complications when 
counselling patients. Treatment decisions are often further complicated by advanced 
patient age, multiple comorbidities and limitations in lung function12. The following 
section presents the main treatments currently available to patients with non small 
cell lung cancer. The same principles of therapy can also be applied to patients with 
small cell lung cancer; however, small cell lung cancer metastasises much earlier in 
the course of disease, and is initially more responsive to systemic chemotherapy13. 
 
1.2.1 Treatment modalities in early stage and locally advanced lung cancer: 
 
Surgical resection is a curative option for some patients with early stage lung 
cancer14. Whenever technically possible, lobectomy is preferred over 
pneumonectomy, as it is associated with a significantly lower loss of lung function 
and exercise capacity15, as well as lower postoperative mortality. A Swiss study 
described mortality rates of 7.9 % following pneumonectomy compared with only 
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1.2% after lobectomy16. A large retrospective analysis of surgical resections in 
Rotterdam also showed higher mortality after pneumonectomy, at 5.7%, compared 
with other types of resection17.  
 
Unfortunately, even early stage, localised NSCLC often recurs after complete 
surgical resection. In addition to local recurrences, which occur in 10-15% of patients 
treated with surgery, many patients develop systemic metastases. The rates of 
systemic recurrence vary significantly with preoperative stage, with 15-30% of 
patients with resected stage I lung cancer, 40% of those with resected stage II, and 
60% with resected stage III disease going on to develop systemic tumour spread18. 
These recurrence rates result in a limited prognosis even for those patients 
diagnosed with early stage, localised disease.  
Additional systemic therapy in the form of adjuvant chemotherapy can slightly reduce 
the chance of recurrence after surgical resection. The Lung Adjuvant Cisplatin 
Evaluation (LACE) study19 investigated the effect of adjuvant cisplatin-based 
chemotherapy in pooled data from 4 584 patients with resected stage I to stage III 
NSCLC, and found that those treated with adjuvant chemotherapy experienced an 
absolute increase in 5-year survival of 5.4% compared with patients who did not 
receive adjuvant chemotherapy. In the LACE study cancer related mortality fell more 
dramatically than overall survival, with a 6.9% decrease in cancer related mortality at 
5 years. However, chemotherapy itself also causes significant toxicity, which may 
have been responsible for the 1.4% increase in non-cancer related mortality 
observed in those patients treated with adjuvant chemotherapy in the LACE study. It 
remains difficult to predict which patients will benefit from adjuvant chemotherapy. 
Unfortunately, many of those treated with adjuvant chemotherapy do not benefit from 
treatment, either because their tumour would not have recurred even without 
additional therapy, or because their tumour recurs despite therapy. Both of these 
groups continue to suffer the toxicity of chemotherapy unnecessarily.  
 
The current guidelines recommend that adjuvant chemotherapy be offered to all fit 
patients with fully resected stage II-IIIa2 NSCLC. Because the benefit of adjuvant 
chemotherapy is less clear in patients with stage I disease, the guideline 
 
8 
 
recommends that patients with stage Ib be offered adjuvant chemotherapy only after 
individual consideration of patient fitness and comorbidities 6. 
In contrast to patient with stage I and II lung cancer, patients with locally advanced 
stage III lung tumours are often not candidates for surgical resection. In general, 
surgery should generally only be offered to these patients as part of a multimodal 
treatment plan6. While some patients with stage IIIa disease benefit from surgery, 
patients with bulky or multi-level N2 lymph node metastases have been shown to 
have poor post-operative survival20, and should therefore not usually be offered 
surgery. Fit patients with inoperable stage IIIa and those with stage IIIb disease can 
be treated with combined radiochemotherapy. Currently, cisplatin and etoposide or 
cisplatin and vinorelbine are often combined with radiation; however, the optimal 
amount, timing and type of chemotherapy have not yet been determined. Although 
simultaneous radiochemotherapy is more effective than sequential radiation and 
chemotherapy21; it is also associated with significant toxicity and may not be suitable 
for patients with large tumours, limited lung function or poor performance status 22. 
Simultaneous radiochemotherapy leads to long term survival in over 20% of patients, 
and is therefore a potentially curative therapy for locally advanced lung cancer23. As 
is the case with adjuvant chemotherapy following curative resection, it is not yet 
possible to predict which patients will benefit from which type of radiochemotherapy.  
 
1.2.2. Treatment of advanced lung cancer 
 
Patients with stage IV lung cancer are generally treated palliatively with platinum 
doublet chemotherapy24. Chemotherapy targets cell proliferation relatively non-
specifically; and many of the side-effects of chemotherapy are a result of these 
drugs’ effects on normal cell division. In advanced NSCLC chemotherapy results in a 
clear survival benefit when compared to best supportive care25.  However, not all 
patients who are treated with chemotherapy respond, and those who do respond 
almost invariably go on to progress within several months of treatment. The most 
frequently used platinum-based chemotherapy doublets have been shown to be 
equally effective in unselected patients26.  
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Currently, the efficacy of a specific chemotherapeutic regimen in an individual patient 
and tumour can only be judged during or after treatment. Several recent studies have 
investigated the use of early imaging, in some cases only days after the first dose of 
therapy, to predict response to a course of systemic treatment27-29. In addition, many 
studies point to an association between specific biomarkers and response to 
particular chemotherapeutic agents. The use of prognostic and predictive biomarkers 
is described in section 1.2.5 below. Although studies are ongoing, predictive 
biomarkers for the efficacy of chemotherapy are not yet established in routine clinical 
use. 
Not all patients can be treated with platinum doublets, either due to comorbidities 
such as renal insufficiency or congestive heart failure, or due to poor performance 
status. These patients are generally treated with single agent chemotherapy or with 
palliative care alone. In some cases a non-platinum based chemotherapy doublet 
may be administered. Recurrences following first-line chemotherapy may be treated 
with second-line therapy, generally single-agent chemotherapy24. 
 
 
1.2.3. Targeted therapies 
 
Over the past several years new treatments for lung cancer have become available. 
Many of these differ from traditional chemotherapeutics in that they target a specific 
molecule or molecular change, which is often part of a cell proliferation signalling 
pathway. The EGFR receptor was the first molecule to be inhibited by a specific 
‘targeted’ therapy in the treatment of lung cancer. Oncogenic mutations in EGFR 
which activate the receptor’s tyrosine kinase domain are found in approximately 15% 
of Caucasian patients with NSCLC30. Inhibition of the intracellular tyrosine kinase 
domain of the EGFR receptor by the tyrosine kinase inhibitors (TKIs) gefitinib 
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(marketed as Iressa) and erlotinib (marketed as Tarceva) results in a reduction in 
EGFR signalling and, therefore, a reduction in tumour growth31. Early trials of EGFR-
TKIs included unselected patients with NSCLC, that is, patients both with and without 
EGFR mutations32. With the exception of erlotinib in second line, these trials failed to 
show an overall benefit with EGFR-TKIs, despite impressive responses in some 
patients31. It was not until subgroup analyses and subsequent prospective trials in 
molecularly defined cohorts showed a benefit in patients whose tumours harbour 
EGFR mutations, particularly mutations in exons 19 and 21, that EGFR-TKIs found a 
clear clinical niche33 34.  
 
Another clinically relevant molecular change in NSCLC is the fusion of the EML4 
gene with the ALK gene, which occurs in approximately 3-5% of Caucasians with 
NSCLC, particularly in patients with adenocarcinoma35. As with EGFR mutations, the 
incidence of EML4-ALK fusion is higher in East-Asian populations36. Patients with 
EML4-ALK fusion benefit from treatment with ALK-TKIs. Crizotinib (marketed as 
Xalkori) is currently the only ALK-TKIs licensed in North America and Europe. 
Because of the design of the trials leading to licensing, this drug is presently only 
licensed for the treatment of patients previously treated with chemotherapy37. As is 
the case with EGFR-TKIs, treatment with ALK-TKIs often results in a relatively good 
partial response or disease stabilisation; however, this is almost invariably followed 
by TKI-resistance and disease progression38. While some genetic changes 
responsible for this secondary resistance have been described, such as the T790M 
mutation in EGFR-mutated NSCLC39, the search for additional mechanisms of 
resistance and treatments to overcome them is ongoing.  
 
 
11 
 
1.2.4 Immunologic Therapies for Lung Cancer: 
 
The immune system plays a critical role in recognising and eliminating tumour cells. 
Micrometastases, for instance in the bone marrow40, exist in many patients with 
otherwise early stage disease, and the observation that many of these patients do 
not go on to develop true clinically relevant metastatic disease despite having 
received only local therapy suggests that the immune system is capable of clearing 
some tumour cells without additional systemic therapy. Several attempts to harness 
the immune system’s anti-tumour capabilities have been investigated in clinical trials. 
There are nonspecific approaches to stimulate the immune defence against lung 
cancer as well as more specific approaches 41,42. A number of therapeutic cancer 
vaccines are under investigation for the treatment of NSCLC. These include an 
allogeneic vaccine derived from irradiated NSCLC cell lines (belagenpumatucel-L), 
protein-specific vaccines (for instance, human recombinant EGF, purified MAGE-A3 
recombinant protein, telomerase) and antigen-specific cancer immunotherapies 
targeting mucin-1. Each immunotherapy differs in its mechanism of antigenic 
stimulus, and many incorporate the use of an immunologic adjuvant to potentiate the 
immune response43 44. 
 
1.2.5. Prognostic and predictive biomarkers 
 
The Oxford dictionary defines a biomarker as “a naturally occurring molecule, gene, 
or characteristic by which a particular pathological or physiological process, disease, 
etc. can be identified” 45. 
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In medical practice, biomarkers can be either prognostic, predictive or both. 
Prognostic biomarkers correlate with the clinical course of disease, often quantified 
as overall survival, independent of which type of therapy is given. In contrast, 
predictive biomarkers correlate with the response to a specific treatment, and can be 
used to select a treatment likely to be effective against a particular tumour 46.  
 
 
1.2.5.1. Prognostic factors 
 
Prognostic markers are clinically useful in the care of patients with lung cancer, as 
they allow clinicians to estimate the likelihood of a particular outcome or course of 
disease. Many clinical attributes and biomarkers have been examined for their 
prognostic value in lung cancer. The stage of disease, the performance status of the 
patient and the histology (in particular the distinction between small cell and non 
small cell lung cancer) are widely accepted prognostic markers47. The prognostic 
relevance of the subgroups of NSCLC is under investigation. Especially in early lung 
cancer the histological subtypes of adenocarcinoma seem to be prognostically 
relevant 7. With the advent of the EGFR-TKIs in advanced NSCLC it was observed 
that the presence of an activating EGFR mutation is itself of prognostic relevance48. 
In the setting of early stage lung cancer the question of whether the mutation itself, or 
rather the clinical characteristics associated with the mutation, such as the absence 
of smoking behaviour, are prognostic remains the subject of debate49 50. Although 
numerous other potentially prognostic biomarkers have been described, the most 
important prognostic factors in clinical practice are still clinical patient characteristics 
such as performance status, generally described using the ECOG or Karnofsky 
scales, and stage of disease.  
 
Prognostic biomarkers are of scientific value because they suggest a strong link, and 
may imply a causal relationship between a characteristic of tumour growth, for 
instance invasiveness or the potential to metastasize, and a specific molecule. For 
many molecules investigated primarily in in vitro models of disease this represents an 
important first step from the bench to the bedside. 
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Clinically, prognostic markers are not able to directly predict the response to specific 
therapies; however, they may be of use in deciding how, or how often, to monitor 
patients for signs of disease progression, or in weighing the risks and benefits of a 
treatment. Biomarkers which correlate with the individual prognosis – especially after 
potentially curative treatment for local disease – may also help determine the need 
for additional systemic treatment. Similarly, for patients with advanced disease, 
prognostic markers may be of value in adapting the amount and intensity of systemic 
therapy, determining the type and frequency of monitoring during and after treatment, 
as well as in discussing palliative treatment decisions with patients and families. 
 
1.2.5.2 Predictive factors 
 
Several predictive markers are relevant for the choice of systemic therapy in 
advanced NSCLC. Histology itself, in particular the distinction between squamous 
cell and non-squamous tumours, is predictive of response to pemetrexed. While 
patients with non squamous NSCLC benefit from pemetrexed, those with squamous 
cell cancer do not 51. Histology is also predictive of the risk of serious side effects 
during treatment with bevacizumab. EGFR mutations are also valuable predictors of 
response to some systemic therapies. An activating EGFR mutation predicts 
response and progression-free survival in patients treated with the EGFR-TKIs 
erlotinib and gefitinib 52,53; and EML4-ALK fusion54 is predictive of response to the 
ALK-TKI crizotinib. Potentially predictive molecular biomarkers for the efficacy of 
specific chemotherapeutic agents have also been described, for example thymidilate 
synthase (TS) for response to pemetrexed and ERCC1 (excision repair cross-
complementing rodent repair deficiency, complementation group 1) for response to 
cisplatin, but these markers have not yet been universally accepted or validated55,56. 
Expression of ERCC1, which plays a role in DNA-repair, was found to be predictive 
of benefit from adjuvant chemotherapy in the Bio-IALT trial 56. However, this finding 
was not reproducible57, and for this reason ERCC1 has not yet found a place in 
routine clinical decision making. Predictive markers for the efficacy of various 
systemic agents in NSCLC would likely help to reduce the rate of primary 
progression under therapy and reduce the risk of unnecessary treatment side effects. 
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1.3.   Early diagnosis and screening of lung cancer  
While early lung cancer is a potentially curable disease, it is often clinically silent and 
therefore goes unrecognised. Even after patients recognise the presence of new or 
changing symptoms, there is often a substantial delay in seeking medical advice, and 
then an additional delay in making the correct diagnosis and in referral to a lung 
cancer specialist 10. 
 
Lung cancer screening 
 
The early detection of lung cancer, that is, the detection of tumours at a potentially 
curable stage, is a clinically important goal. The recently published results of large 
trials of computed tomography (CT)-screening for lung cancer have shown that CT-
screening can find lung cancer at an earlier and thus surgically curable stage. In the 
National Lung Cancer Screening Trial, the risk of lung cancer death was significantly 
lower in those screened on a yearly basis using CT58. However, in addition to lung 
cancer, CT-screening also finds a multitude of non-cancerous lung nodules. The 
expense and risk associated with following and correctly diagnosing these benign 
nodules is enormous59. Screening all smokers for lung cancer using CT alone is not 
feasible in Germany at this time. The widespread implementation of lung cancer 
screening will likely depend on the development of multimodal models of lung cancer 
risk (including lung function, biomarkers, imaging results) to select individuals for 
screening, coupled with a risk-adapted approach to patient follow-up60. A biomarker 
found in easily accessible biomaterials such as sputum, exhaled air or peripheral 
blood could help risk-stratify the population and focus screening on high risk 
individuals. 
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1.4. Biomaterial sampling 
 
A detailed pathological and molecular workup of a tumour specimen, including 
analysis of possible prognostic and predictive markers, requires a sufficient number 
of tumour cells. While resected specimens are almost always large enough for these 
analyses, bronchoscopic biopsies and fine needle aspirations are often much 
smaller, in some cases capturing only a few tumour cells, and therefore present a 
challenge to the pathologist and molecular biologist61. Techniques to optimise the 
yield of small biopsies and aspirates, such as image guidance with endobronchial 
ultrasound or CT, the use of several passes with the aspiration needle, and the cell 
block technique for processing cytological material, are of clinical importance.  
 
1.4.1. Non-invasive and minimally invasive biomaterial sampling 
 
Their potential to limit the morbidity and mortality associated with invasive 
procedures makes non-invasive and minimally invasive techniques appealing in a 
wide range of clinical situations. Minimally invasive biomaterial sampling is especially 
well suited to improve patient care in the setting of lung cancer screening. Because 
97% of CT-detected nodules are non-malignant58 and many of the patients screened 
are heavy smokers with pulmonary comorbidities, the risks and benefits of invasive 
diagnostic procedures have to be weighed carefully when advising this group of 
patients. It is neither feasible nor clinically sensible to biopsy every lesion detected by 
CT. The measurement of biomarkers in minimally invasive samples such as blood, 
lavage and sputum may help assess the risk of cancer in patients with lesions 
detected by screening, or may even help pre-select patients at particularly high risk 
of cancer before screening. 
 
In addition, minimally invasive biomaterial sampling is well-suited to improve the care 
of patients with recurrent tumours or progression after first-line systemic therapy. It is 
difficult to get enough tissue to reach an exact diagnosis and select an individualised 
treatment at the time of first diagnosis, and getting enough tissue to perform repeat 
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molecular analyses as treatment resistance develops and the tumour progresses 
poses an additional challenge. The advent of new molecular targets has taught us to 
look for and treat driver mutations, and when the tumour progresses, to look for new 
changes in the tumour’s biology which may suggest a specific second line 
treatment62. A tumour sample is now not only required at the time of diagnosis, but 
also during the course of disease or at the time of progression63. This shift in our 
approach to lung cancer therapy demands that minimally invasive sampling and 
alternative biomaterials such as serum, bronchoalveolar lavage, and pleural fluid be 
developed to their fullest potential. 
 
 
1.4.2. Bronchoalveolar lavage 
 
Bronchoalveolar lavage (BAL) describes a diagnostic medical procedure in which a 
flexible bronchoscope is used to collect a sample of the epithelial lining fluid (ELF) 
from the small airways and alveoli. The procedure is safe and well established in 
both adult and pediatric patient populations 64, and can be performed using local 
anesthesia and light sedation. During the procedure the bronchoscope is introduced 
into the segment of interest and advanced until a wedge position is reached. Aliquots 
of normal saline are then introduced through the working channel and aspirated 
under negative pressure into a sterile collection vessel. In generalized diseases of 
the lung the right middle lobe is generally chosen as the site of bronchoalveolar 
lavage due to the higher volume and higher total cell count of fluid recovered from 
this lobe 65. The analysis of BAL fluid depends on the clinical indication and situation 
and may include a determination of total and differential cell counts, cell sub-
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populations, identification of cell phenotypes associated with specific exposures and 
disease states and the identification of airway pathogens. 
 
Various patterns of cell differentiation detected in bronchoalveolar lavage samples 
have been shown to correlate with disease states in the lung. This is summarized in 
an American Thoracic Society Clinical Practice Guideline published in 2012 66. 
Normal BAL fluid contains over 85 % macrophages, between 10% and 15% 
lymphocytes, fewer than 3% neutrophils, fewer than 1% eosinophils and fewer than 
5% squamous epithelial or ciliated columnar epithelial cells. Elevated BAL 
eosinophils (>1% eosinophils) correlate with the presence of eosinophilic pneumonia, 
drug-induced pneumonitis, asthma, Churg-Strauss syndrome, allergic 
bronchopulmonary aspergillosis and Hodgkin’s disease, as well as with bacterial, 
fungal, parasite and pneumocystis infections. In contrast, elevated BAL neutrophils 
(>3%) suggest a diagnosis of collagen vascular disease, idiopathic pulmonary 
fibrosis, aspiration pneumonia, bacterial or fungal infection, bronchitis, asbestosis, 
acute respiratory distress syndrome or diffuse alveolar damage; and elevated BAL 
lymphocytes (>15%) suggest a diagnosis of sarcoidosis, non-specific interstitial 
pneumonia, hypersensitivity pneumonitis, collagen vascular diseases, radiation 
pneumonitis, cryptogenic organizing pneumonia or lymphoproliferative disorder. The 
lymphocyte subtypes may also be of diagnostic relevance. For instance, an elevated 
CD4/CD8 ratio suggests a diagnosis of pulmonary sarcoidosis66.  
In addition to changes in the pattern of nucleated immune cells in BAL fluid, the direct 
microscopic identification of infectious organisms or malignant cells in BAL samples 
may lead to a specific diagnosis; the presence of hemorrhagic fluid may suggest 
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pulmonary hemorrhage; and the presence of cloudy or milky fluid may suggest 
pulmonary alveolar proteinosis 66.  
 
In clinical and translational research BAL may also be used to measure the 
concentration of substances thought to have a causal link with pulmonary disease 
states. For instance, gastrooesophageal reflux disease has been clinically linked with 
idiopathic pulmonary fibrosis. This clinical association was corroborated by the 
measurement of pepsin in bronchoalveolar lavage fluid from patients with pulmonary 
fibrosis as recently described by Lee and colleagues67. These investigators found 
significantly elevated pepsin levels in bronchoalveolar lavage from patients with 
acute exacerbations of idiopathic pulmonary fibrosis compared with lavage pepsin 
measurements in samples from patients with stable disease.  
 
 
1.5. IL-22 – discovery, molecular and biological ch aracteristics 
IL-22 was identified in 2000 by Belgian investigators searching for genes induced by 
IL-9 in murine T-cells 68. The group identified a gene encoding a novel protein which 
seemed to be structurally related to the class II cytokine IL-10. This protein was 
initially named IL-10-related T-Cell Derived Inducible Factor (IL-TIF). Shortly 
following its’ discovery, IL-TIF was shown to be present in T-cells, mast cells, thymus 
and brain,68 and to activate signal transducer and activator of transcription -3 (STAT-
3). The human homolog of IL-TIF was found to activate STAT-3 and STAT-1 in 
hepatoma cell lines as well as in several melanoma cell lines 69, and to upregulate 
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expression of acute phase reactants in the liver. Mice injected with E. coli 
lipopolysaccharide showed an acute increase in IL-TIF expression in numerous 
organs including gut, lung, thymus, liver and kidney, which suggested that IL-TIF 
plays a role in the response to inflammation69.  
The same year, an American group identified a novel cytokine produced by activated 
T-cells70. This cytokine, which they named IL-22, was found to be identical to the IL-
TIF cytokine described by the Belgian group. These investigators also identified the 
IL-22 receptor IL-22R, which they found forms a receptor complex with cytokine 
receptor family proteins (CRF), in particular CRF2-470. An IL-22 receptor complex 
consisting of a CRF2-9 chain and an IL-10R2 chain was described in 200171. 
 
Since its’ discovery, IL-22 has been identified in a variety of tissues and cell types 72 
and has been shown to play a role in a wide range of human diseases. IL-22 appears 
to act predominantly on IL22-receptor-1 (IL-22-R1) positive epithelial and endothelial 
cells 73. While, in some settings, IL-22 appears to protect against damage due to 
inflammation, in other settings it seems to contribute to the development and 
persistence of disease74. 
 
In addition to its’ role in the lung, IL-22 has been found in a number of other tissues 
and has been shown to play a role in a number of organ systems. For instance, IL-22 
has been shown to promote wound healing in both the skin and the gastrointestinal 
tract. Boniface and colleagues75 showed that epidermal keratinocytes express a 
functional IL-22 receptor made up of IL-22RA1 and IL-10RB chains. Keratinocytes 
exposed to IL-22 were found to express proinflammatory proteins, and stimulation 
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with IL-22 resulted in keratinocyte migration in an in vitro model. Further evidence for 
the role of IL-22 in tissue repair and healing was published by a group investigating 
the role of STAT3 in epithelial wound healing in the colon76. The investigators 
examined colitis and intestinal wound repair in wild type mice, IL-22 knock-out mice, 
and mice in which the intestinal epithelial cells had been modified to knock out 
STAT3. They found that IL-22 knock- out mice developed more severe colitis than 
their wild type counterparts, and that mucosal healing was also delayed in the IL-22 
deficient animals. In contrast to wild type animals, IL-22 knock-out mice showed very 
little STAT3 activation in response to colitis; however, STAT3 could be induced by 
exposing ex-vivo colon to IL-22. The investigators concluded that IL-22 protects 
intestinal epithelium in the setting of colitis and promotes wound healing through the 
activation of STAT376. 
Protective effects of IL-22 have been also been demonstrated in the setting of liver 
injury and inflammation. Radaeva and colleagues showed that IL-22 protects 
hepatocytes in a mouse model of induced liver injury by inducing the expression of 
antiapoptotic substances 77. Zenewicz and colleagues also investigated the role of IL-
22 in liver injury 78. Using an IL-22 deficient mouse model, the investigators showed 
that IL-22 is protective in acute liver inflammation. In contrast to the wild-type 
animals, many of the homozygous and heterozygous IL-22 deficient mice died shortly 
after induction of liver injury. Th17 cells expressing IL-22 were able to reduce 
hepatocyte damage in the IL-22 deficient mice78. An additional study recently showed 
the administration of IL-22 to be hepatoprotective in a mouse model of ischemic 
reperfusion injury79. 
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In contrast to its’ protective effects during acute inflammation and injury, IL-22 has 
also been shown to promote the development of various disease states, in some 
cases through the promotion of pathological, chronic states of inflammation. 
Transgenic mice engineered to aberrantly express the IL-22 receptor chain IL-22R1 
on lymphocytes showed increased serum levels of IL-22, possibly due to positive 
autoregulation, and died prematurely as a result of multiorgan inflammation 80. The 
investigators were able to show that this increase in IL-22 expression led to systemic 
neutrophilia as well as high levels of inflammatory cytokines in both serum and 
bronchoalveolar lavage samples.  
In the skin, IL-22 has been implicated in the development of psoriasis81 82.  
IL-22 has been also shown to have a proinflammatory role in a mouse model of 
rheumatoid arthritis83. Levels of IL-22 were found to be higher in mice immunized to 
induce arthritis; and IL-22 knock-out mice developed less severe arthritis than their 
wild-type counterparts.  
 
1.5.1. IL-22 in the lung 
 
In the lung, IL-22 has been shown to be expressed by a variety of immune cells 
including T-cell subsets84, monocytes and alveolar macrophages, as well as in 
primary lung alveolar epithelial cells 85 and cultured human bronchial epithelial cells 
86. Whittington and colleagues measured IL-22 in a variety of pulmonary samples 
including bronchoalveolar lavage samples from patients with acute respiratory 
distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF), pulmonary 
sarcoidosis and post-operative ventilated patients with no known lung pathology, as 
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well as in paraffin-embedded macroscopically normal lung tissue from patients 
undergoing lung cancer resection. These investigators were able to show that 
alveolar macrophages and alveolar epithelial cells in normal lung tissue express IL-
22, and that levels of IL-22 in lavage are lower in patients with pulmonary sarcoidosis 
than in both normal controls and patients with idiopathic pulmonary fibrosis. They 
also found that IL-22 binding protein is expressed in alveolar macrophages, alveolar 
epithelial cells, monocytes and neutrophils; and that only alveolar epithelial cells 
express the IL-22 receptor chain IL-22R185. 
 
IL-22 in non-malignant lung diseases 
IL-22 seems to have a dual role in lung diseases, acting to protect the lung in the 
setting of some types of acute lung inflammation or injury while promoting 
inflammation and pulmonary disease in other settings. 
In a model of ventilator-induced lung injury, inhaled IL-22 was shown to protect rats 
exposed to barotrauma against lung injury87. 
In the setting of allergic asthma there is evidence that IL-22 reduces airway 
inflammation and bronchoconstriction. Schnyder and colleagues studied the role of 
IL-22 in a mouse model of the allergic response. They found that IL-22 is produced in 
the lungs of mice exposed to ovalbumin, where it inhibits dendritic cell function and 
eosinophil recruitment thus negatively regulating the allergic response 88.  
Further evidence for the anti-allergic properties of IL-22 was published by Taube and 
colleagues, who studied airway hyperresponsiveness in IL-22 deficient mice. The 
authors found increased inflammation and increased airway hyperresponsiveness in 
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animals deficient in IL-22, and decreased inflammation in those treated with 
intranasal IL-22 before antigen challenge. They conclude that IL-22 protects against 
inflammation and allergy-related airway constriction89.  
In contrast, work from Besnard and colleagues suggested that IL-22 may have a dual 
role in allergic asthma, and may not always protect the lung 90. These investigators 
studied both patient samples and a mouse model of induced allergic asthma and 
found elevated levels of serum IL-22 in both asthmatic patients and mice. Mice 
deficient in IL-22 showed fewer measurable signs of asthma, including less airway 
hyperreactivity and mucus production and lower levels of Th2 cytokines. However, 
mice in which IL-22 was downregulated at the time of antigen challenge seemed to 
show increased allergic inflammation. The authors conclude that “IL-22 is required for 
the onset of allergic asthma, but functions as a negative regulator of established 
allergic inflammation” 90. A recently published review summarizes the current 
understanding of the role of IL-22 in allergic asthma, concluding that the function of 
IL-22 may vary with the stage of asthma pathogenesis.91 
 
The role of IL-22 in the setting of fungal, bacterial and viral pulmonary infections has 
also been investigated by a number of groups. Gessner and colleagues examined 
the role of IL-22 in a mouse model of pulmonary Aspergillus fumigatus infection and 
found that A. fumigatus exposure induces Il-22 expression in the lung in wild type 
mice, with a reduction of this effect in Dectin-1 deficient mice. IL-22 deficient mice 
showed higher levels of A. fumigatus in the lung than those without IL-22 deficiency. 
Both Dectin-1 deficiency and IL-22 deficiency also appeared to result in a lack of 
soluble anti-fungal molecules in the lung, suggesting that IL-22 contributes 
significantly to the lung’s innate defense against Aspergillus infection92. In addition, 
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there is evidence that IL-22 contributes to the immune defence against candidiasis93. 
The possible role of IL-22 in the immune response to fungal infections was recently 
reviewed by Zelante and colleagues94.  
 
IL-22 also appears to have a role in the immune response to bacterial pneumonia. 
Aujla and colleagues used a mouse model of Klebsiella pneumoniae pneumonia to 
investigate the role of IL-22 in gram negative pneumonia 86. IL-22 was elevated in the 
lung tissue of Klebsiella pneumoniae infected mice compared to control mice, and 
this IL-22 was found to originate from T-cells in the lung. Administration of an IL-22 
antibody resulted in infection-related mortality. IL-22 was also shown to have 
antimicrobial properties against K. pneumoniae in vitro 86. Additional evidence for the 
role of IL-22 in bacterial infection was provided by Zheng and colleagues, who used a 
mouse model of intestinal bacterial infection to show that IL-22 is induced during 
infection. In comparison to wild-type animals, IL-22 knockout mice were not able to 
clear infection with Citrobacter rodentium and suffered high rates of systemic 
bacterial spread and infection related mortality 95.  
 
The role of IL-22 in viral pneumonia was recently investigated by Pociask and 
colleagues in a mouse model of influenza infection96. Both IL-22 knockout and wild-
type mice were able to clear the influenza infection; however, IL-22 knockout mice 
showed signs of more severe lung injury, decreases in lung compliance and 
increased collagen deposition in the lung. The authors conclude that IL-22 mediates 
airway repair processes following influenza pneumonia. 
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IL-22 appears to play a role in the response to a range of pulmonary pathogens, as 
well as in numerous non-malignant pulmonary disorders. The effects of IL-22 in the 
lung, as in many other organs, seem to be both immunoregulatory and 
proinflammatory depending on the type and stage of disease74. 
 
 
1.5.2. IL-22 in lung cancer 
 
To date, the literature concerning IL-22 in cancer has remained somewhat 
contradictory, with some evidence suggesting that IL-22 protects against tumour 
growth, and other studies suggesting that IL-22 contributes to or supports the 
malignant potential of tumour cells.  
 
Xing and colleagues were able to show that IL-22 protects hepatocytes from 
apoptosis in a model of alcohol-induced hepatotoxicity97. In the setting of malignancy, 
the anti-apoptotic effects of IL-22 may protect tumour cells. Radaeva and colleagues 
described the anti-apoptotic effects of IL-22 in the hepatocellular carcinoma cell line 
HepG277. HepG2 cells engineered to over-express IL-22 were resistant to apoptosis 
in vitro. The overexpression of IL-22 also resulted in increased tumour formation in a 
subcutaneous tumour model in nude mice. The anti-apoptotic effects of IL-22 
appeared to be related to upregulation of the antiapoptotic proteins Bcl-xL, Bcl-2 and 
Mcl-1 and the mitogenic proteins c-myc, cyclin D1, Rb2 and CDK477. 
There is also evidence that IL-22 may be relevant to the development of human 
cancers. Thompson and colleagues found an association between the single 
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nucleotide polymorphism rs1179251 in IL-22 and risk of colon cancer in a mostly 
Caucasian population 98.  
Contradictory evidence, suggesting that IL-22 may inhibit cancer cells, was published 
by Weber and colleagues, who examined the role of IL-22 in breast cancer cell lines 
99. These investigators found that while EMT6 murine breast cancer cells express IL-
22R, exposure to IL-22 inhibits cancer cell proliferation and leads to cell cycle arrest. 
In a subcutaneous tumour model in nude mice, they found that treatment with IL-22 
decreased tumour growth. 
 
IL-22 has been shown to be expressed in lung cancer cell lines and primary tissues, 
and seems to promote tumour growth in this disease. A recent project at our centre 
showed that IL-22R1 is expressed by the lung cancer cell lines A549, HCC827, 
H1339, H187 and LOU-NH91. Although the lung cancer cell lines themselves were 
not found to express IL-22, exposure to IL-22 induced proliferation of the cell lines in 
vitro100. Cells selected for resistance to cisplatin showed upregulation of IL-22R1. 
Upon exposure to IL-22, these cisplatin-resistant cells showed increased proliferation 
compared with cisplatin naïve cells, suggesting that IL-22 signalling may correlate 
with a more aggressive tumour phenotype 101.  
These findings correlate well with previously published evidence from Zhang and 
colleagues, who described expression of IL-22 in lung adenocarcinoma and 
squamous cell carcinoma tissue, as well as higher IL-22 concentrations in the serum 
and pleural effusion of lung cancer patients compared to control patients without lung 
cancer102. These investigators also found expression of IL-22 receptors in the lung 
cancer cell lines A549 and PG, and expression of IL-22 in A549 cells. Cell lines 
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overexpressing IL-22 were resistant to chemotherapy-induced apoptosis. IL-22 
silencing with small interfering RNA resulted in increased tumour cell apoptosis, and 
decreased tumour growth in a subcutaneous xenograft model in nude mice 102. 
 
Immunohistochemical staining of tissue microarray samples from over 2000 patients 
has shown that IL-22 is expressed in both small cell and non-small cell lung 
cancers103. However, IL-22 expression in the tumours tested by Kobold and 
colleagues did not correlate with tumour stage or prognosis. And so, although IL-22 
promotes tumour cell proliferation in vitro, the clinical impact of IL-22 in lung cancer 
patients remains unclear.  
 
Despite uncertainty as to the precise nature of IL-22s’ role in malignancy, it seems 
clear that IL-22 is relevant not only to primary lung cancer, but also to non-malignant 
lung diseases. For this reason, we sought to quantify IL-22 in the pulmonary 
compartment, as sampled by bronchoalveolar lavage and bronchial washings, in 
patients with lung cancer compared with patients with non-malignant pulmonary 
disorders and infections. In order to characterize the concentration of IL-22 in these 
groups, we analysed specimens from 56 patients undergoing clinically indicated 
lavage at our hospital and correlated IL-22 concentration in the lavage samples with 
both local and systemic cell counts and with serum markers of inflammation. 
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1.6. Aim of the dissertation 
 
The aim of this dissertation is to investigate the feasibility of IL-22 measurements in 
bronchial washings and bronchoalveolar lavage in patients with lung cancer and 
patients with non-malignant lung illnesses, and to describe the correlation of IL-22 
concentration with local and systemic cell differentiation and systemic inflammation. 
We hypothesize that IL-22 in lavage reflects the lung compartment, and may 
therefore serve as a biomarker for physiological and pathological processes localized 
to the lung. 
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2. PATIENTS AND METHODS 
 
Patients underwent routine diagnostic or therapeutic flexible bronchoscopy with 
lavage in the Respiratory Medicine and Thoracic Oncology Section of the Internal 
Medicine Department V (Medizinische Klinik V, Sektion Pneumologie Innenstadt und 
Thorakale Onkologie), Ludwig Maximilians University of Munich, Germany. 
Bronchoscopy and lavage were carried out as clinically indicated and following 
written informed consent. Excess lavage material was used for IL-22 analysis. The 
study and its protocol were approved by the local ethics board (Ethikkommission der 
Universität München, decision number EK 376-11). 
 
 
2.1. Patients 
 
Adult men and women undergoing clinically indicated diagnostic or therapeutic 
flexible bronchoscopy on an outpatient or inpatient basis in the Department of 
Pneumology were included in the study. Patients were not excluded or selected 
based on suspected diagnosis, stage of disease or concurrent medication. The 
routine diagnostic evaluation included appropriate imaging, blood work, lung function 
analyses, biopsies and cultures as clinically indicated. Patient information was 
gathered retrospectively from the chart and electronic patient records. The diagnosis 
of the treating physician following routine analysis of the bronchoscopic samples was 
recorded. For the purpose of analysis diagnosis categories were then created, 
namely lung cancer, other thoracic malignancies (including primary intra-thoracic 
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cancers and metastases from other sites), pneumonia, other lung diseases, and a 
reference cohort made up of patients who underwent bronchoscopy due to 
suspected lung disease or malignancy which were not confirmed by the results of the 
bronchoscopy and clinical work-up.  
 
 
2.2. Bronchoscopic Procedures and Sample Collection  
 
2.2.1. Bronchoscopic procedures 
 
Bronchoalveolar lavage (BAL) and bronchial washings were performed as clinically 
indicated and according to standard clinical practice at our centre, which is based on 
peer-reviewed international recommendations 66. During bronchoscopy blood oxygen 
saturation and heart rate were monitored continually, and non-invasive blood 
pressure was measured at regular intervals. Following local anesthesia of the nares 
and pharynx, patients underwent conscious sedation with titrated midazolam with or 
without the additional administration of intravenous propofol, and were intubated 
nasally with a flexible bronchoscope. Following inspection of the laryngeal anatomy 
the vocal cords were anesthetised with a topical local anesthetic. The bronchoscope 
was then advanced into the trachea.  
 
Bronchoalveolar lavage  
 
For bronchoalveolar lavage (BAL) the bronchoscope was advanced into wedge 
position, preferentially in the segment of clinical interest or, in the case of diffuse 
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pulmonary pathology, in the right middle lobe. Normal saline was instilled in 20 ml 
aliquots to a total volume of 120 to 160 ml and was retrieved into a sterile container 
using suction.  
 
For bronchial washings the bronchoscope was introduced into the area of clinical 
interest, which in most cases was the segment thought to be affected by infection or 
tumour, and normal saline (generally 40 to 80 ml) was instilled and retrieved using 
suction. A standard morphological and immunologic analysis of BAL cellular 
components was performed and included total cell count, differential count of 
macrophages, lymphocytes and neutrophils as well as flow cytometry analysis of the 
lymphocyte subsets, including BAL CD4/CD8 T-cell ratio. Differential cell count 
(leukocytes, lymphocytes, neutrophils, macrophages and CD4/CD8 ratio) subgroups 
were based on standard cut-off values used for the interpretation of BAL fluid66. 
 
 
 
2.2.2. Sample processing 
 
The volume of lavage fluid retrieved was recorded and samples were then divided in 
the bronchoscopy suite according to clinical indication. Aliquots for microbiological 
and pathological analyses were labelled and set aside. The remaining lavage fluid 
was transported without delay at room temperature to the on-site pneumology 
laboratory and processed immediately. The fluid was filtered through a triple layer of 
sterile gauze to remove mucous and large particles. Fifteen millilitres of filtered BAL 
fluid were then set aside for fluorescence activated cell sorting (FACS) analyses and 
two or more 500 microlitre aliquots were frozen at -20 degrees Celsius for later 
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enzyme-linked immunosorbent assay (ELISA) analysis. The remaining BAL fluid was 
used to determine cell count and differential cell count. 
 
2.2.2.1 Cell count 
 
One hundred microliters of the filtered BAL fluid was combined with one hundred 
microliters of sterile water and one hundred microlitres of crystal violet and mixed 
briefly with a vortex mixer. Ten microliters of this suspension was then pipetted into a 
Neubauer cell counting chamber and cells were counted manually under light 
microscopy. 
 
2.2.2.2 Differential cell count 
 
Cytospin samples were prepared by cytocentrifugation using between one hundred 
and three hundred microliters of filtered BAL fluid, depending on the cell count of the 
sample. From each patient sample, two cytospin slides were stained with Giemsa 
solution and May-Grünwald stain, and two further unstained cytospin slides were 
fixed with methanol and archived. The percentage of macrophages, neutrophils, 
lymphocytes and eosinophils was determined by manually counting at least 300 cells 
using light microscopy.  
 
2.2.2.3. CD4/CD8 Ratio 
 
Fluorescence activated cell sorting was used to determine the proportion of CD4 and 
CD8 positive lymphocytes in the BAL samples. For FACS analyses, fifteen millilitres 
of filtered BAL fluid was centrifuged and the supernatant was poured off. Twenty 
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millilitres of red cell lysis solution was added to the cell pellet, the cells were 
resuspended using a vortex mixer, and the solution was allowed to stand at room 
temperature for ten minutes before being centrifuged once again. The supernatant 
was poured off, and the cell pellet was resuspended in twenty millilitres of phosphate 
buffered saline (PBS), centrifuged, and the resulting cell pellet resuspended in 500 
microliters of PBS. Three aliquots were prepared for FACS analysis, each with one 
hundred microliters of cell suspension: one unstained, one with twenty microliters of 
Simultest reagent, and one with twenty microliters of MultiTest reagent. One millilitre 
of PBS was then added to the Simultest and MultiTest aliquots, the samples were 
centrifuged, and a few drops of PBS were added to the cell pellets. FACS analysis 
was then carried out using a FACSCalibur flow cytometer.  
 
 
2.2.2.4. IL-22 ELISA 
 
Enyzme-linked immunosorbent assays (ELISA) for IL-22 detection were obtained 
from R&D, Abington, UK. ELISA analyses were performed in the Department of 
Clinical Pharmacology (Prof. S. Endres and Dr. S. Kobold). In brief, 50 µl of diluted 
samples (in triplicates) were loaded and incubated for 2 h at room temperature (RT). 
Detection antibody was applied for 2 h at RT and streptavidin-bound horseradish 
peroxidase (HRP) was added for 20 min at RT. Absorption was measured at 450 nm 
using a Mithras reader (Berthold Technologies, Bad Wildbad, Germany). The 
detection limit of the ELISA was 15 pg/ml.  
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2.3. Statistical Methods 
 
For comparative analysis between two groups (paired comparisons) only data from 
samples above the detection limit of the ELISA (> 15 pg/ml) were used. For the IL-22 
levels, mean values of three independent experiments each performed in triplicates 
were calculated and used for subsequent analysis. GraphPad Prism Software, 
version 5.0b (GraphPad Software) was used. All t-tests were unpaired and 2-sided 
and p values < 0.05 were considered significant.  
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3. RESULTS 
 
We analysed lavage specimens from 56 patients undergoing clinically indicated 
bronchoscopic lavage and correlated IL-22 expression with local and systemic cell 
counts and with serum markers of inflammation.  
 
3.1. Cohort demographics 
 
Samples from 56 adult in-patients and out-patients who underwent routine 
bronchoscopy in the Respiratory Medicine and Thoracic Oncology Section of the 
Internal Medicine Department V (Medizinische Klinik V, Sektion Pneumologie 
Innenstadt und Thorakale Onkologie), Ludwig Maximilians University of Munich, 
Germany were included in the analysis. Samples (43 bronchoalveolar lavages and 
13 bronchial washings) were collected from twenty women and thirty-six men. The 
patients ranged in age from 18 to 84 years, with a mean age of 58.3 years. Most 
patients were adults aged sixty-one to eighty years (thirty-one patients), or forty-one 
to sixty years (fourteen patients). Nine patients were between twenty-one and forty 
years of age, one patient was younger than twenty years of age, and one was older 
than eighty.  
 
The diagnostic evaluation included bronchoscopy and appropriate imaging, blood 
work, biopsies and cultures as indicated, and revealed sixteen patients (29%) with 
infection. Three of these patients had tuberculosis and thirteen had other bacterial 
pneumonias. Fourteen patients (25%) had a diagnosis of lung cancer, with thirteen 
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cases of non-small-cell lung cancer and one case of small cell lung cancer. Seven 
patients (13%) had other thoracic malignancies or pulmonary metastases from 
extrathoracic tumours. The diagnostic work-up revealed eleven patients with other 
lung diseases, including one patient with Wegener’s granulomatosis, one patient with 
chronic graft rejection following lung transplantation, two patients with acute 
respiratory distress syndrome (ARDS), four patients with interstitial lung disease or 
fibrosis and three patients with sarcoidosis. Nine patients underwent bronchoscopy 
due to a suspected lung disease or malignancy which was not confirmed by the 
results of the bronchoscopy and clinical work-up. These patients were therefore 
included in the reference cohort.  
 
3.2. IL-22 concentration in BAL and bronchial washi ngs 
 
IL-22 is found in significant amounts in lavage sam ples 
 
In thirty-five of the fifty-six samples analysed, the measured level of IL-22 was above 
the limit of detection of the ELISA (Figure 1A). In the remaining twenty-one samples 
no IL-22 was detected, or the measured level of IL-22 was below the limit of 
detection (Figure 1A). The average IL-22 level in all samples with detectable IL-22 
was 44 pg/ml (range 15 -121 pg/ml). The average IL-22 concentrations in the BAL 
samples and the bronchial washings were similar at 47 pg/ml and 33 pg/ml, 
respectively (difference not statistically significant).  
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IL-22 concentration does not correlate with gender or age 
 
The average IL-22 concentration in samples from male (45 pg/ml) and female (48 
pg/ml) patients was not significantly different, with an average IL-22 concentration of 
45 pg/ml in samples from men, and an average IL-22 concentration of 48 pg/ml in 
samples from women. The average IL-22 concentration in samples from patients 
older than the mean cohort age (58.3 years) did not differ significantly from the 
concentration in younger patients. Patients above the mean age had an average IL-
22 concentration of 41 pg/ml, while those below the mean age had an average IL-22 
concentration of 54 pg/ml. There was also no clear correlation with age in subgroups 
of patients aged under twenty years, twenty-one to forty years, forty-one to sixty 
years, sixty-one to eighty years and over eighty years.  
 
3.3. Correlation of IL-22 with diagnosis 
 
Patients with lung diseases have higher IL-22 concentrations in lavage samples. 
The 29 patients with a lavage IL-22 concentration above the detection limit included 
twenty-three patients with confirmed lung disease and six patients without lung 
disease. IL-22 levels were significantly higher in patients with lung disease (50 pg/ml) 
compared to those of patients without lung disease (26 pg/ml). This is shown in figure 
1B. Subgroup analyses for a relationship between specific diagnosis and IL-22 
concentration revealed a trend towards higher IL-22 levels in patients with bacterial 
pneumonia (53 pg/ml), patients with NSCLC (44 pg/ml) and patients with pulmonary 
manifestations of other malignancies (57 pg/ml) compared to patients without lung 
disease (26 pg/ml). Table 1 provides a summary of the demographic characteristics 
and diagnoses of the patients included in this study, as well as the IL-22 
concentration in subgroups based on gender, age and diagnosis. 
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FIGURE 1: 
IL-22 concentrations in lavage are higher in patients with lung diseases than in 
controls. 
 
Figure 1A:  Dot plot analysis of IL-22 concentrations found in n = 56 lavage samples. 
The detection limit is 15 pg/ml (continuous black line). The mean ± SEM for all 
patients is indicated in the graph. Figure 1B:  Comparison between BAL IL-22 
concentrations for samples above the detection limit of patients with and without lung 
disease. Each dot represents the mean value of three independent measurements by 
ELISA, each performed in triplicates. Means ± SEM are indicated for both groups. 
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TABLE 1 
 
Correlation of Patient Characteristics with IL-22 in the Lavage 
 
 
Characteristics 
Number of 
patients (% of 
study cohort) 
IL-22 [pg/ml] 
(mean of all 
values) 
IL-22 [pg/ml] 
(mean of values 
above DL) 
Number of samples 
below DL (%) 
      
Gender     
Male 36 (64.3%) 29 45 14 (38.8) 
Female 20 (35.7%) 24 48 12 (60) 
      
Age (years)     
< 20 1 (2%) 11 n.a. 1 (100) 
21-40 9 (16%) 41 56 3 (33.3) 
41-60 14 (25%) 21 63 10 (71.4) 
61-80 31 (55%) 25 39 13 (41.9) 
> 80 1 (2%) 43 43 0 (0) 
     
Diagnosis     
Pneumonia 13 (23.6%) 32 53 6 (46.2) 
NSCLC 13 (23.6%) 28 44 6 (46.2) 
SCLC 1 (1.8%) 9 n.a. 1 (100) 
Sarcoidosis 3 (5.4%) 27 40 1 (33.3) 
Tuberculosis 3 (5.4%) 23 37 1 (33.3) 
Cancer (non 
lung) 7 (12.7%) 29 57 4 (57.1) 
Wegener 
granulomatosis 1 (1.8%) 70 70 0 (0) 
ILD 4 (7.3%) 11 41 3 (75) 
ARDS 2 (3.6%) 11 14 2 (100) 
GVHD 1 (1.8%) 64 64 0 (0) 
Control (no lung 
disease) 9 (16.4%) 19 26 3 (33.3) 
 
n.a. stands for not applicable. 
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3.4. Correlation of IL-22 with cellular components of BAL 
 
IL-22 does not correlate with the cell count in BAL  
 
IL22 concentration did not show a significant association with the overall cell counts 
in the BAL fluid. These results are summarized in table 2, along with the mean IL-22 
concentrations in subgroups based on differential cell counts in the BAL and 
systemic markers of inflammation. 
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TABLE 2 
Correlation of BAL Parameters and Systemic Parameters with IL-22 in the Lavage 
 
Characteristics 
Number of 
patients (% of 
study cohort) 
IL-22 [pg/ml] 
(mean of all 
values) 
IL-22 [pg/ml] 
(mean of values 
above DL) 
Number of samples 
below DL (%) 
BAL parameters     
Cells/ml     
< 100,000/ml 14 (25.4%) 33 56 6 
≥ 100,000/ml 16 (29.1%) 25 45 8 
% Lymphocytes     
< 10% 15 (27.3%) 26 39 6 
≥ 10% 13 (23.6%) 30 72 8 
CD4/CD8 ratio     
CD4/CD8 < 1,3 8 (14.5%) 16 33 6 
CD4/CD8 > 1,3 14 (25.4%) 34 66 7 
% Neutrophils     
< 5% 14 (25.4%) 44 58 8 
≥ 5% 13 (23.6%) 16 32 4 
% Macrophages     
< 80% 10 (18.2%) 37 48 2 
≥ 80% 18 (32.7%) 23 55 12 
      
Peripheral blood 
parameters     
CRP (mg/dl)     
< 0,5 13 (23.6%) 27 42 5 
≥ 0,5 40 (72,7%) 27 46 19 
Leukocytes (G/l)     
< 11 42 (76.4%) 24 41 20 
≥ 11 12 (21.8%) 32 46 5 
Lymphocytes 
(cells/µl)     
< 1500 21 (38.2%) 25 47 11 
≥ 1500 12 (21.8%) 26 42 5 
 
Samples were analyzed according to clinical indication, therefore some categories 
describe fewer than 56 samples; n.a. stands for not applicable. 
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IL-22 correlates with a higher proportion of lympho cytes in BAL 
 
IL-22 concentration in BAL samples was compared with the cell differentiation in the 
BAL. IL-22 concentrations were significantly higher in patients with an elevated 
proportion of lymphocytes in the BAL fluid (IL-22 72 pg/ml for ≥ 10% lymphocytes vs. 
39 pg/ml for < 10% lymphocytes, p=0.029. This is shown in figure 2A.  
 
IL-22 correlates with a higher CD4/CD8 lymphocyte r atio in BAL 
 
IL-22 was higher in the subgroup of patients with an elevated CD4/CD8 ratio 
compared to those with a lower CD4/CD8 ratio. Patients with a CD4/CD8 ratio equal 
to or greater than 1.3 had an average IL-22 concentration of 66 pg/ml, whereas 
patients with a CD4/CD8 ratio below 1.3 had an average IL-22 concentration of 33 
pg/ml, p=0.033. These results are summarized in figure 2B.  
 
 
IL-22 does not significantly correlate with the pro portion of neutrophils in BAL 
 
There was a numerical trend towards lower IL-22 concentrations in patients with 
higher BAL neutrophils; however, this did not reach statistical significance.  The 
average IL-22 concentration was 58 pg/ml for patients with less than 5 % neutrophils 
in the BAL, compared to an average IL-22 concentration of 32 pg/ml for patients with 
greater than or equal to 5% neutrophils in the BAL. These results are summarized in 
figure 2C. 
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IL-22 does not correlate with the proportion of mac rophages in BAL 
 
There was no significant correlation between IL-22 concentration and the proportion 
of macrophages in the BAL. The average IL-22 concentration in the BAL was 55 
pg/ml for samples with greater than 80 % macrophages, compared to an average IL-
22 concentration of 48 pg/ml for BAL samples with less than 80% macrophages. 
These results are summarized in figure 2D.  
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Figure 2:  
IL-22 concentrations in BAL are higher in patients with a higher proportion of BAL 
CD4+ lymphocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A:  Comparison of IL-22 concentrations found in BAL samples with a normal 
(<10%) and a high proportion of lymphocytes (>10%). Figure 2B:  Comparison of IL-
22 concentrations found in BAL samples with a normal (<1.3) and a high CD4/CD8 
ratio (>1.3). Figure 2C:  Comparison of IL-22 concentrations found in BAL samples 
with a normal (<5%) and a high proportion of neutrophils (>5%). Figure 2D:  
A 
D C 
B 
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Comparison of IL-22 concentrations found in BAL samples with a normal (<80%) and 
a high proportion of macrophages (>80%). One dot represents the mean value of 
three independent ELISA measurements. Means ± SEM are indicated for all groups. 
 
 
3.5. Correlation of IL-22 with systemic markers of inflammation 
 
In order to assess the possibility that IL-22 concentrations measured in the lung are a 
product of systemic inflammation, IL-22 concentration in lavage was compared with 
standard clinically relevant indicators of systemic inflammation and infection, namely 
systemic levels of C-reactive protein (CRP) as well as systemic leukocyte and 
lymphocyte counts. 
 
IL-22 in lavage does not correlate with systemic le ukocyte counts 
 
There was no significant correlation between IL-22 concentration in the lung, as 
sampled by lavage, and leukocyte count in the peripheral blood. Lavage IL-22 levels 
in patients with systemic leukocytes below 11 G/l did not differ significantly from 
those from patients with higher systemic leukocyte counts. Patients with leukocyte 
counts below 11 G/l showed an average lavage IL-22 concentration of 41 pg/ml; and 
patients with elevated leukocyte counts (above 11 G/l) showed an average IL-22 
concentration of 46 pg/ml. These results are summarized graphically in figure 3A.  
 
IL-22 in lavage does not correlate with systemic ly mphocyte counts 
 
As with systemic leukocyte counts, absolute lymphocyte counts in peripheral blood 
did not show any significant association with IL-22 concentration in lavage. The 
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average IL-22 concentration in lavage from patients with low systemic lymphocyte 
counts (lymphocytes < 1500/µl) was 47 pg/ml. Patients with high systemic 
lymphocyte counts (lymphocytes > 1500/µl) had an average IL-22 concentration in 
lavage of 42 pg/ml. The lavage IL-22 concentration in these patients is shown in 
figure 3B.  
 
IL-22 in lavage does not correlate with systemic CR P-levels 
 
Serum CRP levels showed no correlation with IL-22 concentration in lavage. Patients 
with a clinically elevated CRP level (≥ 0.5 mg/dl) had an average pulmonary IL-22 
concentration in lavage of 46 pg/ml. This was similar to the IL-22 concentration in 
lavage from patients with non-elevated systemic CRP levels (CRP < 0.5 mg/dl), 
which was measured to be 42 pg/ml. This data is summarized in figure 3C. 
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Figure 3  
 
IL-22 concentrations in lavage do not correlate with systemic parameters of 
inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3A : Comparison of IL-22 concentrations found in lavage from patients with a 
normal (< 11 G/ml) and a high (> 11 G/ml leukocyte count in the peripheral blood). 
Figure 3B : Comparison of IL-22 concentrations found in lavage from patients with a 
normal (< 1500) and a high (> 1500) lymphocyte count in the peripheral blood. 
A B 
C 
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Figure 3C:  Comparison of IL-22 concentrations found in lavage from patients with a 
normal (< 0.5 mg/dl) and a high (≥ 0.5 mg/dl) serum CRP concentrations. 
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4. DISCUSSION 
 
This study established that IL-22 is found in the airways of patients with a variety of 
pulmonary diseases including lung cancer patients, and can be measured in lavage 
samples using ELISA. IL-22 in lavage is elevated in patients with lung cancer and in 
patients with pneumonia compared to individuals with no bronchoscopic evidence of 
pulmonary disease. IL-22 concentrations in lavage correlate with cell differentiation in 
the BAL but not with systemic cell counts and CRP, suggesting that lavage IL-22 
levels represent processes localized to the lung. Lavage IL-22 may therefore prove to 
be a valuable biomarker in patients with lung cancer. 
 
4.1. Discussion of the methods 
 
4.1.1. Diversity of patients and diagnoses 
 
This study included patients with a variety of clinical diagnoses, spanning a broad 
range of pathologies encountered in the practice of respiratory medicine, and ranging 
in age from young adults to the elderly. This diversity represents an important 
advantage of the study design and increases the potential to translate the results to 
clinical practice. Patients with lung cancer often suffer from additional pulmonary 
comorbidities. Although smoking-related diseases such as chronic bronchitis and 
emphysema are the most common, patients with other pulmonary pathologies such 
as idiopathic pulmonary fibrosis are also at an increased risk of developing lung 
cancer, as are individuals with occupational exposures to substances such as 
silica104. In addition, recent large lung cancer screening trials have shown that many 
of those screened for lung cancer show radiographic evidence of other lung 
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diseases105,106. It is, therefore, crucial that lung cancer biomarkers intended for 
diagnostic use be able to distinguish not only lung cancer cases from healthy 
individuals without lung disease, but also lung cancer cases from benign pulmonary 
pathologies.  
 
In the current study, levels of IL-22 in lavage were highest in patients with lung 
cancer, patients with other pulmonary malignancies and patients with pneumonia. 
Levels were lower in patients with no bronchoscopic evidence of pulmonary disease, 
although all of these patients had clinical symptoms, which had led to the indication 
for bronchoscopy. Although the study also included patients with interstitial lung 
diseases, this subgroup was too small to allow for meaningful statistical analysis. The 
IL-22 concentrations measured in the current study showed a significant overlap 
between patients with lung cancer and patients with bacterial pneumonia. Strategies 
to differentiate these patient populations from another, perhaps through the use of 
serial measurements after antibiotic treatment, quantification of IL-22 in the systemic 
circulation, or the measurement of additional markers in the lavage fluid, are the 
subject of an ongoing project in our department.  
 
4.1.2. Inclusion of washings and bronchoalveolar lavage 
 
This study included patient samples collected by two distinct means, namely 
bronchoalveolar lavage and bronchial washing. Although similar, these two 
procedures do not sample identical regions of the airways. While bronchoalveolar 
lavage aims to collect cells from the alveoli, the clinical goal of a bronchial washing is 
generally to sample material from a more proximal airway. This is most often of 
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relevance when the pathological process to be sampled, for instance the suspected 
tumour, is localised centrally. In such cases a sample collected from the more distal 
airways is less likely to lead to a diagnosis than a sample collected proximally. 
Although generally safe and well tolerated, bronchoalveolar lavage may cause 
transient decreases in arterial oxygen saturation in patients with severe respiratory 
insufficiency107. The clinician may therefore find it prudent to limit the amount of 
saline used to collect a bronchoalveolar lavage sample in critically ill patients or those 
with significant pre-existing limitations of gas exchange. In some such cases the 
clinician may elect to perform a bronchial washing rather than a bronchoalveolar 
lavage, especially if the clinical situation does not require alveolar sampling. For 
instance, in patients with severe pneumonia undergoing bronchoscopy for the 
purpose of establishing a microbiological diagnosis, a bronchial washing may be 
more clinically appropriate than a bronchoalveolar lavage. Because this study aimed 
to examine the feasibility of IL-22 measurements in routine samples, both types of 
sample, that is, both bronchoalveolar lavage and bronchial washings, were included. 
A retrospective subgroup analysis comparing the washings with bronchoalveolar 
lavage showed no significant difference in mean IL-22 concentration; however, the 
subgroups may have been too small to detect such a difference. 
 
The anatomy, functionality and cellular composition of the airways vary from the 
trachea through the large central airways and into the alveoli. It is therefore not only 
possible but also quite likely that, rather than representing a single compartment, the 
airways represent several interrelated compartments which may be sampled 
differently depending on the precise position of the bronchoscope. Whether this is of 
relevance for the measurement of IL-22 concentration and characterisation of IL-22 
signalling in the lung has yet to be established.  
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This study analysed samples collected by experienced clinicians in routine practice, 
without seeking to influence the collection method or type of sample collected. 
Because a bronchoalveolar lavage is more often clinically indicated in patients 
suspected of having interstitial lung diseases, and a washing may be more often 
indicated when the clinical suspicion is tumour, it is not possible to rule out that 
systematic bias in the type of sample collected from different patient subgroups may 
have somewhat influenced the results. 
 
4.1.3. Dilution of Samples 
 
Bronchoalveolar lavage seeks to sample the lung’s epithelial lining fluid (ELF). 
However, because lavage involves the introduction and then aspiration of saline into 
the airways, there is an unavoidable dilution of the ELF sample, and the degree of 
dilution may vary between procedures and between patients. It is, therefore, difficult 
to measure the exact concentration of substances in the epithelial lining fluid itself. 
There have been numerous attempts to correct for this dilution in previous studies. 
While some of these approaches have sought to correlate the serum and lavage 
concentrations of molecules such as albumin or urea, others have used a dilutional 
approach, measuring the concentration of markers in the fluid introduced into and the 
fluid removed from the airways. However, the precision of each of these techniques 
is limited by the complex physiology of the diffusion of molecules across the blood-air 
barrier, which has also been shown to vary with different disease states108,109. 
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Based on the assumption that urea diffuses freely from the blood into the epithelial 
lining fluid of the lung, Rennard and colleagues110 compared blood urea levels with 
urea concentrations in bronchoalveolar lavage in order to estimate the degree of 
dilution in lavage samples. They performed lavage with normal saline, and found that 
the concentration of urea in the recovered samples was approximately 1% of the 
serum urea concentration.  
 
Jones and colleagues compared the use of urea and albumin as measures of dilution 
in bronchoalveolar lavage in sixty-seven patients with a variety of pulmonary 
diseases, and found significant variability in lavage albumin concentrations between 
patients109. The authors concluded that urea is a superior marker of dilution in lavage 
samples compared with albumin. However, the use of urea as a marker is also not 
unproblematic, as urea likely does not diffuse as freely into the lung as previously 
thought. There is now evidence that multiple factors, including the timing of cigarette 
smoking before bronchoscopy, may influence the urea permeability of the blood-air 
barrier in the small airways108. 
 
Complicating both the use of urea and albumin as markers of dilution is the 
observation that dwell time, that is, the time which saline is allowed to remain in the 
airways before being aspirated, affects the concentration of urea, glucose and 
albumin in lavage samples. This is likely due to diffusion of these molecules from the 
blood into the lavage fluid110. 
 
Ward and colleagues examined the use of albumin as a marker of dilution in 
lavage108. These investigators used injections of radioactive albumin in the systemic 
circulation to estimate the contribution of the diffusion of albumin from the systemic 
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circulation to the total albumin measured in lavage samples. There was a trend 
toward higher flux of albumin from the systemic circulation in asthmatic compared to 
healthy subjects undergoing lavage. 
 
 
Baughman and colleagues described the use of methylene blue introduced in the 
lavage fluid as a marker of dilution111. Interestingly, these investigators found that the 
albumin concentration in BAL fluid varied with the diagnosis, suggesting that 
corrections for the dilution of samples based on albumin may not be reliable in all 
groups of patients.  
Another technique based on the dilution of a marker introduced into the lavage fluid 
was described by Restrick and colleagues, who performed bronchoalveolar lavage in 
mild asthmatics as well as healthy controls using the inert polysaccharide inulin at a 
concentration of 0.1mM in the instilled fluid as a marker of dilution. These 
investigators found that the use of inulin as a marker in lavage was well tolerated by 
both the asthmatic and healthy subjects. They calculated that epithelial lining fluid 
made up an average of 7.0% of the fluid recovered from asthmatics and 9.4% of the 
fluid recovered from healthy subjects. However, there was significant variability 
between subjects, with epithelial lining fluid accounting for between 2% and 23% of 
the fluid recovered from the airways112. 
 
Although at our hospital bronchoalveolar lavage is performed in a standardized 
fashion, the amount of normal saline instilled during the procedure may vary slightly 
from clinician to clinician. In this study we did not correct for the effect of dilution in 
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the samples collected. Therefore, the IL-22 concentrations which were measured in 
the present study can not directly reflect the absolute IL-22 concentration in the 
epithelial lining fluid of the lung. The true concentration of IL-22 in the epithelial lining 
fluid is likely higher than the concentration measured in the uncorrected lavage 
samples. In addition, the variability observed between patient samples may in part 
have been due to varying degrees of dilution during sample collection. Absolute cell 
count may correlate with the degree of dilution in lavage samples; however, we did 
not find a significant correlation between absolute cell count in the lavage and lavage 
IL-22 concentration. 
 
4.1.4. Correlation with Systemic Parameters 
 
This study compared IL-22 concentrations measured in lavage with markers of 
systemic inflammation, namely with systemic leukocyte counts and with serum CRP 
levels. We were able to show that IL-22 concentration in the lung seems to be 
independent of these makers of systemic inflammation. However, as the study 
protocol did not include the collection of additional blood samples for the purpose of 
systemic IL-22 measurements, we were not able to directly assess possible 
differences in systemic and local IL-22 concentration. Previous studies have 
examined the differential expression of various substances including microRNAs113, 
114 in the systemic circulation and in the lung and have often found differences in the 
concentration in these two compartments. It is therefore not unlikely that IL-22 
concentration also differs between the systemic circulation and the lung. The 
concentration of IL-22 in the systemic circulation as well as in other compartments 
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such as the pleural fluid is currently being addressed by an ongoing project at our 
institution.  
 
The expression of the systemic markers of inflammation examined in this study may 
be affected by medications such as corticosteroids. Because the current study did 
not document the type and timing of medications administered to the patients 
sampled, a retrospective analysis of the possible confounding effect of such 
medications on the assessment of systemic inflammation is not possible.  
 
4.2.  Discussion of the results  
 
4.2.1. IL-22 in Lavage 
 
To date, there is little published data on IL-22 in bronchial lavage fluid. To our 
knowledge, no previous studies have investigated the concentration of IL-22 in 
lavage samples from patients with lung cancer. However, there is some evidence 
from groups studying other patient populations that IL-22 can be reliably measured in 
lavage.  
 
A study from Whittington and colleagues examined IL-22 concentration in 
bronchoalveolar lavage samples from patients with non-malignant lung diseases, 
finding IL-22 concentrations in epithelial lining fluid (ELF) in the range of 0 to 15 
ng/microliter, with significant variability between subgroups of patients85. The present 
study reports on IL-22 concentration in the total lavage fluid and not in the epithelial 
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lining fluid, and so, as expected, the concentrations reported in the present study are 
lower than those reported in the Whittington study. 
A recent study in bronchoalveolar lavage samples from patients suffering from 
bronchial asthma revealed that IL22 concentration is elevated in asthmatic subjects 
compared to healthy controls115, with an IL-22 concentration in lavage of 0.159 pg/ml 
in controls and 0.709 pg/ml in asthmatics.  
 
Whittington and colleagues measured IL-22 concentration in lavage in patients with 
acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis, 
pulmonary sarcoidosis and control patients without known lung disease who were 
ventilated postoperatively. The investigators found lower IL-22 concentrations in 
samples from patients with ARDS compared with the ventilated control patients 
without lung disease85.  
The finding of lower IL-22 concentrations in lavage from patients with pulmonary 
diseases compared to normal controls is in disagreement with the finding of the 
present study. Our data showed a significantly higher concentration of IL-22 in lavage 
from patients with pulmonary illnesses compared to controls. This discrepancy may 
be explained by the fact that the Whittington study used post-operative ventilated 
patients without lung disease as controls, whereas the control patients in our study 
were not intubated and ventilated, and had not undergone surgery on the day of 
lavage. It is well established that mechanical ventilation can cause lung injury 116, 
which may have contributed to higher IL-22 levels in this group of patients. Our data 
agree with the data from Pennino and colleagues, which also showed higher 
concentrations of IL-22 in lavage samples from patients with pulmonary disease 
compared with controls 115. 
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4.2.2. The correlation of IL-22 in lavage with clinical pathology 
 
The present study found that patients with bacterial pneumonia, NSCLC or 
pulmonary manifestations of other tumours appear to have higher levels of IL-22 in 
bronchoalveolar lavage and bronchial washings compared with a reference 
population with no bronchoscopic evidence of lung disease. This finding is in line with 
published evidence supporting a role for IL-22 in both lung cancer and in pneumonia.  
 
Studies on the host response towards bacterial or fungal pneumonia have revealed 
that IL-22 contributes both to the acute phase, where it seems to support clearance 
of the infection, and to the chronic phase, where it may prolong inflammation 117 86. In 
chronic infections such as tuberculosis, IL22 seems to play a disease-supporting 
role118. The present study detected a trend towards higher levels of IL-22 in lavage 
samples from patients with pneumonia compared with controls, supporting the 
suggestion that IL-22 plays a role in the pulmonary response to infection. 
 
The finding that patients with lung cancer show relatively high levels of IL-22 in 
pulmonary lavage specimens is also in line with the results of a previous study which 
reported that lung cancer cells express IL-22102. Zhang and colleagues found high 
expression of IL-22 in primary tumour tissue, serum, and malignant pleural effusion 
from NSCLC patients, as well as expression of IL-22 and the IL-22 receptor (IL22-
R1) in lung cancer cell lines. In addition, a study from our institution recently showed 
that IL-22 is expressed in tissue microarray samples of a large cohort of lung cancer 
patients, in particular in patients with large and small cell lung cancers103. The cohort 
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of lung cancer patients in the present study is too small to attempt to confirm this 
variability in IL-22 expression between histological subgroups; however, the finding 
that IL-22 is expressed in lung cancer tissue correlates with our finding of elevated 
lavage IL-22 in these patients.  
 
IL-22 concentration in lavage was quite variable between the individual patients we 
sampled, and not all of the patients with lung cancer in our study cohort showed 
elevated levels of IL-22 in the lavage. IL-22 was above the limit of detection in seven 
out of thirteen lavage samples (53.8%) from patients with NSCLC. This finding 
correlates well with the previous finding from Kobold and colleagues who detected IL-
22 in 23-54% of NSCLC samples in tissue microarrays, depending on histological 
subtype103. It seems likely that not all lung cancers express IL-22 to the same 
degree, and that the expression of IL-22 may also vary during the course of the 
disease. This biological variability may be one cause of the clinical variability 
observed in the course of disease and response to treatment of lung cancer patients.  
 
Although, to the best of our knowledge, the present study is the first to show that IL-
22 is elevated in lavage samples from lung cancer patients, a wide range of other 
potential biomarkers found in lavage have been previously investigated in lung 
cancer 119 120 121. The minimally-invasive nature of flexible bronchoscopy and the 
relative safety of lavage compared with other procedures make bronchoalveolar 
lavage and bronchial washings an appealing means of collecting diagnostically 
valuable material from the local tumour environment in lung cancer patients. 
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4.2.3. Correlation of IL-22 with parameters in lavage and in the systemic 
circulation 
 
 
Correlation with differential cell counts in the BAL 
The present study found that IL-22 concentration in the lavage fluid correlated with a 
high lymphocyte count in the lavage. In addition, lavage IL-22 concentrations 
correlated with a high lavage CD4/CD8 ratio. There was a trend towards a negative 
correlation of lavage IL-22 with lavage neutrophil counts; and a correlation with 
lavage macrophage counts was not identified. These correlations add to the existing 
body of evidence that IL-22 is mainly produced by lymphoid cells, among others by 
CD4-positive lymphocytes 122 123.  
In a previous study which analysed BAL samples in patients with tuberculosis, T 
helper cells were identified as the major source of IL-22 production in BAL fluid123. In 
our current study, we show that IL-22 production, presumably by CD4-positive 
lymphocytes in the lung, is not restricted to tuberculosis but also detectable in other 
lung diseases including lung cancer and other bacterial pneumonias. 
 
Whittington and colleagues85 previously published evidence that a number of cell 
types, including alveolar macrophages, also produce IL-22 in the lung. In the current 
study we did not find a correlation between the percentage of alveolar macrophages 
in the BAL fluid and the concentration of IL-22 in lavage. However, it remains 
possible that some of the IL-22 we detected was produced by macrophages or other 
immune cell populations, but that the relative amount of IL-22 produced by these 
cells was too little to significantly alter the overall concentration of IL-22 in the BAL. 
 
61 
In addition, lung cancer cells themselves may have directly contributed to the 
production of IL-22 in the lung cancer patients sampled. Zhang and colleagues found 
that lung cancer tissue strongly expresses IL-22, and that autocrine feedback loops 
may contribute to IL-22 signalling in lung cancer102. Even peripheral lung tumours 
can be detected at a molecular level in BAL fluid124. It seems, therefore, quite 
possible that IL-22 produced by lung cancer cells may also be detectable in lavage. 
 
Correlation of BAL IL-22 with markers of systemic inflammation: 
Recently, IL-22 has been detected in lavage samples from patients with community-
acquired pneumonia and correlated with serum levels of IL-22 125. Interestingly, these 
authors reported that serum levels of IL-22 were elevated in patients with pneumonia 
compared to healthy controls, but that BAL IL-22 was similar in both groups. They 
also found that BAL fluid from patients with pneumonia contained an increased 
proportion of CD4 T-cells positive for IL-17A and IL-22 compared to blood, and that 
the proportion of these cells in the BAL did not correlate with the proportion in the 
systemic circulation. However, patients admitted to the intensive care unit had a 
higher proportion of IL17A and IL-22 positive CD4 T-cells in their blood. Taken 
together, these data seem to suggest that IL-22 can be simultaneously involved in 
both local and systemic inflammation, but that the systemic inflammatory response 
and the local response in the lung do not always result in the same levels of IL-22 
expression and signalling.  
 
In the present study, we found a dissociation between local IL-22 concentrations and 
systemic leukocyte counts, systemic lymphocyte counts and the clinically relevant 
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systemic parameter of inflammation CRP. In addition, the IL-22 concentrations in 
lavage correlated with local cell differentiation, which seems to suggest that the IL-22 
measured in the lavage reflects local processes in the lung rather than simply 
mirroring systemic inflammation.  
 
The concept of the airways and the lung as a distinct biological compartment with 
cytokine levels differing from those in the systemic circulation is supported by 
previous studies: Hollander and colleagues 126 found that the concentrations of IL-8 
and of other markers of inflammation were significantly higher in BAL samples 
compared to serum samples in patients with bronchial asthma and COPD.  
 
Because lung cancer is very often a systemic illness, it is possible that systemic 
levels of IL-22, and not only local levels in the lung as measured by lavage, may be 
elevated in this disease. Other investigators have reported elevated serum levels of 
IL-22 in non-malignant systemic illnesses. For instance, IL-22 was detected in the 
systemic circulation of 83.5% of patients with Crohn’s disease, compared with only 
16.1% of healthy controls 127. Similarly, Paats and colleagues128 also recently 
reported that the cytokine profiles in CD4+ and CD8+ T-cells in the systemic 
circulation correlate with the severity of chronic obstructive lung disease and, in part, 
also with smoking status. Currently there is a project underway in our department to 
collect simultaneous BAL and serum samples from patients with lung cancer in order 
to directly compare the expression of IL-22 in the systemic and pulmonary 
environments in these patients.  
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Differential cytokine expression in various biological compartments has been found to 
be of relevance in other types of cancer. In the setting of ovarian cancer, there is a 
growing interest in measurements of cytokine levels in ascites fluid as a prognostic 
marker for disease progression in this biological compartment. Giuntoli and 
colleagues129 examined matched ascites and serum samples from thirty-seven 
patients with ovarian, fallopian tube or primary peritoneal cancer and used a 
multiplex assay to measure a number of cytokines. They found significant differences 
in serum and ascites concentrations of many of the cytokines measured. In addition, 
the authors describe a significant correlation between the CD4/CD8 ratio in ascites 
and overall survival. Patients with an ascites CD4/CD8 ratio under 1.6 had a median 
survival of over three years, whereas patients with higher CD4/CD8 ratios (CD4/CD8 
over 1.6) in their ascites fluid lived only an average of 1.3 years. 
Although these investigators did not directly measure IL-22 concentration in the 
ascites fluid, their finding that elevated CD4/CD8 ratios also correlate with a poor 
tumour-related prognosis seems to suggest that similar immunregulatory cell 
populations may be involved. 
 
4.2.4. Correlation with patient demographics 
 
The current study did not find any significant correlation between IL-22 concentration 
in the lavage and patient characteristics such as age and gender. Interestingly, there 
is some recent evidence that levels of serum IL-22 are higher in very elderly 
individuals. Basile and colleagues130 compared IL-22 concentrations in serum in 
healthy centenarians to a group of elderly controls aged sixty to ninety-five years, 
and found an average serum IL-22 concentration of 45.7pg/ml in the centenarians 
compared to 11.1 pg/ml in the control population (p=0.031). Our study was not 
designed to detect such differences in age-based subgroups, and included only one 
patient over eighty years of age. 
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4.2.5 Future Directions 
 
The diagnostic and therapeutic options available to clinicians treating patients with 
lung cancer are rapidly expanding. However, with an increasing number of options 
comes an increasing complexity. The challenge of choosing not only the most 
appropriate therapy for a particular patient, but also of identifying the most 
appropriate time to change to another therapeutic approach, will continue to 
increase. Biomarkers which can guide this clinical decision making will likely be of 
importance; and IL-22 measurements not only at one point in time, but also over the 
course of disease and treatment, may prove helpful. However, additional studies to 
describe the longitudinal course of IL-22 expression during disease and its’ 
correlation with the response or progression of a tumour during therapy are needed 
before the possible clinical uses of IL-22 measurement can be assessed.  
 
IL-22 is an especially appealing but also potentially complex biomarker in lung cancer 
because it seems to have a regulatory role in both infections of the lung and in lung 
cancer itself. In clinical practice these entities often coexist in the same patient, for 
instance in the case of pneumonia caused by the retention of secretions distal to a 
malignant stenosis, or pneumonia in an immunosuppressed tumour patient following 
chemotherapy. In addition, non-infectious pulmonary inflammatory reactions following 
radiation therapy or chemotherapy are not uncommon, and whether these reactions 
are associated with changes in IL-22 signalling is not yet known. Although 
distinguishing these entities from another is often critical to patient assessment, 
 
65 
radiological imaging studies alone are often unable to clearly differentiate tumour 
from atelectasis or pneumonia. And, because these entities are all associated with 
increased uptake of glucose, standard FDG-PET is not always helpful. A better 
understanding of the differential role of IL-22 in infection, inflammation and in tumour 
may lead to the development of biomarkers or biomarker panels capable of 
distinguishing and assessing these entities. 
 
The possibility of manipulating IL-22 or its’ receptor as a therapy for lung cancer or a 
means of improving the response to existing therapies may also be of future interest. 
Our previous collaborative projects have suggested that cisplatin resistant cells 
respond to IL-22 differently than non-resistant cells101. Alterations in the expression 
or signalling of IL-22 may, therefore, prove to alter the susceptibility of lung cancer 
cells to specific treatments.  
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5. CONCLUSION 
 
IL-22 can be measured in pulmonary lavage samples using ELISA, and the 
concentration of IL-22 in lavage correlates with the presence and type of underlying 
lung disease. Lavage IL-22 concentrations are highest in patients with pneumonia 
and in patients with lung cancer, and lowest in patients without bronchoscopic 
evidence of lung disease. IL-22 concentration in BAL is associated with high BAL 
lymphocyte counts and with the CD4/CD8 ratio in BAL but not with overall cell counts 
in BAL. This finding corroborates previous evidence that IL-22 is produced by CD4-
positive lymphocytes. IL-22 concentration in lavage was not found to correlate with 
serum CRP levels or blood leukocyte and lymphocyte counts. This suggests that the 
IL-22 measured in the lavage is produced locally and is not simply the result of 
systemic inflammation. Therefore, lavage may represent a distinct compartment for 
disease processes in the lung, where IL-22 can be studied as a potential lung cancer 
biomarker.
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7. Summary 
 
Background and Aims:  
Lung cancer is not only common, but also difficult to diagnose and to treat. Lung 
cancer screening using CT may help identify tumours in a curable stage, but 
screening also finds a large number of benign changes which are often difficult to 
distinguish from cancer. Patients treated for lung cancer, either with local or 
multimodal therapies in early stage disease or with systemic therapy in advanced 
disease, often go on to progress or relapse despite an initial response to treatment. 
Biomarkers are needed to identify patients at a high risk of lung cancer, to help select 
the most appropriate treatment for an individual patient, and to follow patients during 
the course of the disease. Ideally, these biomarkers should be measurable in non-
invasive or minimally invasive samples, such as bronchoalveolar lavage (BAL) and 
bronchial washings, to avoid the need for repeated invasive, potentially harmful, 
procedures.  
Interleukin-22 (IL-22) may prove to be an informative biomarker in lung cancer. IL-22 
is expressed by T-cell subpopulations in a number of inflammatory and infectious 
disease states, including many pulmonary diseases. IL-22 and its’ receptor have 
been identified in lung cancer cell lines and human lung cancer biopsies. In addition, 
IL-22 signalling appears to promote the growth, and perhaps also chemotherapy 
resistance, of lung cancer in vitro.  
The aim of this dissertation is to investigate the measurement of IL-22 in BAL and 
bronchial washing in patients with lung cancer compared with both patients with non-
malignant pulmonary illnesses and a reference cohort. By correlating IL-22 with 
differential cell counts in the BAL as well as with systemic cell counts and markers of 
inflammation, we hope to assess the suitability of IL-22 in lavage as a biomarker for 
the local pulmonary environment in lung cancer.  
 
Methods: 
Lavage samples were collected from patients undergoing routine flexible 
bronchoscopy with BAL or bronchial washings at the Respiratory Medicine and 
Thoracic Oncology Section of the Internal Medicine Department V (Medizinische 
Klinik V, Sektion Pneumologie Innenstadt und Thorakale Onkologie), Ludwig 
 
104 
 
Maximilians University of Munich, Germany. Cell counts and differential cell counts 
were determined in BAL samples, and IL-22 was measured using ELISA. Systemic C 
reactive protein (CRP) levels and differential blood counts as well as patient 
demographic and medical information were collected from the electronic patient 
record.  
 
Results: 
Lavage samples from 56 patients were analysed. These included samples from 36 
men and 20 women, average age 58.3 years, with lung cancer (25%), infection 
(29%), other thoracic malignancies (13%), other non-malignant pulmonary illnesses 
(14%) and no bronchoscopic evidence of disease (16%). We found IL-22 in 53% of 
the 56 patient samples. IL-22 was higher in patients with lung disease than in 
controls, and patients with pneumonia and those with lung cancer had the highest 
concentrations of IL-22 in lavage. IL-22 concentrations were higher in patients with 
elevated BAL lymphocytes and with high BAL CD4/CD8 lymphocyte ratios. Blood 
leukocyte and lymphocyte counts and serum CRP levels did not correlate with lavage 
IL-22 concentrations. 
 
Conclusion:  
Lavage IL-22 concentrations are high in patients with lung cancer and in patients with 
pneumonia. IL-22 in lavage is associated with lymphocyte counts and CD4/CD8 ratio 
in BAL, as would be expected for a cytokine produced by CD4-positive lymphocytes. 
IL-22 in lavage was not associated with the systemic markers of inflammation tested. 
These results suggest that IL-22 in lavage represents local IL-22 expression in the 
lung. The measurement of IL-22 in lavage warrants further study as a biomarker in 
lung cancer. 
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8. Zusammenfassung 
 
Hintergrund und Ziele:  
 
Das Lungenkarzinom ist eine häufige Krankheit und stellt bei der Diagnosestellung 
sowie bei der Therapie eine besondere Herausforderung dar. Obwohl es durch CT-
Screening möglich ist, Tumoren in einem frühen und auch heilbaren Stadium zu 
identifizieren, werden durch Screening-Untersuchungen auch eine hohe Anzahl an 
gutartige Veränderungen identifiziert, die zum Teil eine invasiven Abklärung 
bedürfen. In frühen Stadien steht meistens eine lokale oder multimodale Therapie im 
Vordergrund. Bei fortgeschrittenen Tumoren wird eine systemische Therapie 
verabreicht. Bei vielen Patienten kommt es nach initialer Therapie zu einem Rezidiv 
oder zur Progression der Erkrankung. Der Kliniker braucht prognostische und 
prädiktive Biomarker um Patienten mit einem hohen Lungenkrebsrisiko zu 
identifizieren und um die optimale Therapie für den individuellen Patienten 
auszusuchen. Dies gilt auch für die Erkennung des Rezidivs während der 
Nachsorge. Um die möglichen Komplikationen eines invasiven Eingriffs zu 
minimieren, sollte der ideale Biomarker auch in nicht- oder wenig-invasiven Proben, 
z.B. der bronchoalveolären Lavage, messbar sein.   
Interleukin-22 (IL-22) könnte sich als Lungenkrebsbiomarker etablieren. IL-22 wird 
von Untergruppen von T-Zellen bei unterschiedlichen infektiösen sowie 
inflammatorischen Krankheiten, unter anderem auch Lungenkrankheiten, exprimiert. 
IL-22 und der IL-22-Rezeptor wurden auch in Lungenkrebszelllinien sowie in 
Biopsiematerial von Lungenkrebspatienten identifiziert. IL-22 scheint das Wachstum 
und eventuell auch die Chemotherapieresistenz von Lungenkrebszellen in vitro zu 
unterstützen  
Ziel dieser Arbeit war es, IL-22 in Lavageproben von Patienten mit Lungenkrebs zu 
messen, und mit IL-22-Messungen von Patienten mit gutartigen Lungenkrankheiten 
und Kontrollen zu vergleichen. Wir korrelierten IL-22 mit der Zellzahl und 
Differenzierung in der BAL sowie mit systemischen Entzündungsparametern wie 
erhöhten Leukozytenzahlen und dem Differentialblutbild sowie dem CRP, um IL-22 in 
der Lavage als Biomarker für die Lokalverhältnisse in der Lunge beim 
Lungenkarzinom zu untersuchen. 
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Methoden: 
Lavageproben wurden bei Patienten, die sich zur flexiblen Bronchoskopie in der 
Medizinischen Klinik V, Sektion Pneumologie Innenstadt und Thorakale Onkologie 
vorstellten, gesammelt. Zellzahl und Zelldifferenzierung wurden bestimmt und IL-22 
wurde mittels ELISA gemessen. Die Parameter im peripheren Blut (CRP, 
Leukozytenzahl und Lymphozytenzahl) sowie Informationen zum Patienten und die 
Diagnose wurden aus dem klinischen Informationssystem erfasst. 
 
 
Ergebnisse:  
Lavageproben von 56 Patienten wurden analysiert, darunter 36 Männer und 20 
Frauen. Das Durchschnittsalter lag bei 58,3 Jahren. Die Diagnosen waren: 
Lungenkarzinom (25%), Pneumonie (29%), andere thorakale Tumoren (13%), 
andere Lungenkrankheiten (14%) und Kontrollen ohne bronchoskopische Hinweise 
auf Lungenpathologie (16%). IL-22 wurde in 53% der Patientenproben detektiert. Die 
IL-22-Konzentration in der Lavage war in Vergleich mit der Kontrollgruppe bei 
Patienten mit Lungenkrankheiten höher, und besonders hoch bei Patienten mit 
Lungenkrebs und Patienten mit Pneumonie. Die IL-22-Konzentration in der BAL 
korrelierte mit erhöhten Lymphozyten und einem hohen CD4/CD8 Quotienten in der 
BAL. Die systemischen Entzündungsparameter inklusive Leukozytenzahl, 
Lymphozytenzahl und CRP korrelierten mit der IL-22-Konzentration in der Lavage 
nicht. 
 
Schlussfolgerung:  
Die IL-22-Konzentration ist in der Lavage von Patienten mit Lungenkrebs sowie von 
Patienten mit Pneumonie erhöht. IL-22 in der Lavage ist mit einer hohen 
Lymphozytenzahl sowie einem hohen CD4/CD8-Quotienten in der BAL assoziiert. 
Dieses Ergebnis unterstützt die Vermutung, dass IL-22 hauptsächlich von CD4-
positiven Lymphozyten produziert wird. Die IL-22 Konzentration in der Lavage zeigte 
keine Korrelation mit den gemessenen systemischen Entzündungsparametern. 
Zusammenfassend deuten diese Ergebnisse darauf hin, dass IL-22 in Lavage mit der 
lokalen IL-22 Expression in der Lunge korreliert. IL-22 in der Lavage könnte ein 
wertvoller Lungenkrebsbiomarker werden. 
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